19 Amendments of João FERREIRA related to 2020/2071(INI)
Amendment 78 #
Motion for a resolution
Recital C
Recital C
C. whereas the loss of EuropeanU Member State sovereignty and independence in the health sector is linked to medicines and health equipment sector and withe relocation of production, with 40 % of medicinal end products marketed in the EU now originating in third countries; whereas the only way to save money is to rely heavily on subcontractors to produce pharmaceutical raw materials in Asia, where labour costs and environmental standards are lower, with the result that 80 % of active ingrediengard to raw materials is linked to deindustrialisation and the relocation of production by the pharmaceuticals giants, with 40 % of medicinal end products mare manufactured outside the EU, mainly in China and Indiaketed in the EU now originating in third countries;
Amendment 168 #
Motion for a resolution
Recital H a (new)
Recital H a (new)
Ha. whereas medicine shortage notification mechanisms for supply chain operators and pharmacists in particular are currently very fragmented in the Member States; whereas this could prevent adequate monitoring and communication between Member State authorities regarding medicine shortages;
Amendment 184 #
Motion for a resolution
Recital J a (new)
Recital J a (new)
Ja. whereas the COVID-19 outbreak has highlighted the importance of countries having sovereignty and a reasonable capacity for ensuring their own supplies of medicines and medical equipment, especially in view of the restricted intra-Community movement of goods and the arbitrary retention of equipment in the wake of the outbreak;
Amendment 205 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Stresses the geostrategic imperative that the Union regain itsMember States step up their sovereignty and independence with regard to health care and secure its supply of medicines and medical equipment;
Amendment 214 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Points out that, that while public health policies are a Member State matter, it is the incumbent upon the EU to coordinate and complementhe EU can and must support national measures to guarantee affordable and high- quality health services for European citizens;
Amendment 283 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls on the Commission and the Member States to take whatever action is needed to restore Europeantheir health sovereignty and local pharmaceutical manufacturing, giving priority to essential and strategic medicines; calls on the Commission to map out existing and potential production sites in the EU at national level, identifying possible instances of complementarity;
Amendment 301 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
Amendment 303 #
Motion for a resolution
Paragraph 4 b (new)
Paragraph 4 b (new)
4b. Points out that, since the beginning of the health crisis, community pharmacists have displayed commitment and determination to ensure that patients have ongoing access to necessary medicines 24 hours a day and seven days a week; recognises that community pharmacists, due to their proximity to patients, have been the first line of counselling, treatment and referral for many patients suffering from common ailments, helping to ease the pressure on the emergency services and other levels of health care;
Amendment 318 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
Amendment 360 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Calls on the Commission to ensure that its pharmaceutical strategy is guaranteed to combat inadmissible business practices anywhere on the medicines circuit that might undermine transparency and balanced relations between the various public and private entities directly or indirectly involved in ensuring access to medicines, fulfilling an essential public service;
Amendment 395 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Stresses that the urgent need for medicines and medical equipment must not mean compromising the quality, safety, efficacy and cost-effectiveness of medicines for human use and health products;
Amendment 405 #
Motion for a resolution
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Stresses the urgent need to ensure that pharmaceutical patents do not impede supplies in the event of a shortage of medicines; stresses the need to secure necessary supplies at times of crisis or during any present and future epidemic outbreak by replacing pharmaceutical patents for medicines, vaccines and medical equipment with licences for public laboratories and manufacturers to supply generic copies of branded products without the need to negotiate with patent holders;
Amendment 465 #
Motion for a resolution
Paragraph 11 a (new)
Paragraph 11 a (new)
11a. Stresses the need to ensure that health professionals and the general public have access to safe, effective and good quality medicines and health products by monitoring and regulating continued compliance with good clinical practice regarding the authorisation of clinical trials and the conduct thereof, in line with the highest health protection standards;
Amendment 497 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Recommends the introduction of centralised management to bring about greater transparency in the distribution chain and the creation of a European supply management unit tasked with developing a Europeansupporting Member State strategyies to prevent and resolve breaks in supply;
Amendment 545 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Calls on the Commission to create a Europeansupport the creation of Member State contingency reserves of medicines of strategic importance for health care, supplies of which are critical, along the lines of the ‘RescEU’ mechanism, in order to alleviate shortages outside crisis periods;
Amendment 602 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. Calls on the Commission and Member States to seek closer collaboration and exchanges of best practice in efforts to mitigate the impact of medicine shortages, for example by giving pharmacists greater latitude to better manage patient care and ensure continuity of treatment;
Amendment 662 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18a. Calls on the Member States to develop effective governance systems to improve collaboration between all supply chain operators and the national authorities in order to increase the efficiency and effectiveness of joint notification and evaluation procedures; calls on the Member States and the European Medicines Agency (EMA) to further step up their collaboration to improve notification, monitoring and reporting procedures regarding medicine shortages;
Amendment 706 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20a. Calls on the Commission and Member States to improve channels of reporting and communication between all supply chain operators and the national authorities, developing policies and strategies for the notification of medicine shortages in line with the following principles: (a) ensuring greater transparency and availability of data regarding medicine shortages; (b) encouraging the early detection and central appraisal of possible shortages by means of reliable notification systems linking all medicine supply chain operators and the national authorities; (c) increasing access to information available along the entire supply chain.
Amendment 740 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Recalls the words of the United Nations Secretary-General, who recently stated that future COVID-19 treatment is ‘a public good’ that should be made available to all; warns that public health protection is incompatible with the desire for profit, which can only be satisfied through the suffering of the many;